Analysis updated on Oct. 16, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq
Our AI ranks Repligen Corp outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
Repligen Corp is a mid-cap company with a market capitalization of $9.90B. It ranks number 13 by market capitalization among the 60 Biological Products, (No Diagnostic Substances) issuers in our coverage with a current forecast. Its P/E Ratio of 254.21x is the highest of the 15 peers that report one.
For RGEN, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 62.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 54.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.8%, buy ≥ +0.2%, sell < -0.9%, strong sell < -1.2% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-16 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, RGEN included.
Follow RGEN free90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Biological Products, (No Diagnostic Substances) peers listed below that report each metric.
| Metric | RGEN | Rank |
|---|---|---|
| Market Cap | $9.90B | 13/60 |
| P/E Ratio | 254.21x | 1/15 |
| P/B Ratio | 4.69x | 25/49 |
| EPS | $0.69 | – |
| Book Value/Share | $37.42 | – |
| Revenue/Share | $13.91 | – |
| FCF/Share | $1.98 | – |
| Metric | RGEN | Rank |
|---|---|---|
| ROE | 2.0% | 14/47 |
| ROA | 1.4% | 14/50 |
| ROIC | 2.3% | 14/53 |
| Gross Margin | 53.8% | 19/24 |
| Operating Margin | 8.2% | 12/40 |
| Net Margin | 5.3% | 13/37 |
| EBT Margin | 6.6% | 13/42 |
| Tax Rate | 20.4% | – |
| Metric | RGEN | Rank |
|---|---|---|
| Current Ratio | 9.05x | 18/59 |
| Quick Ratio | 7.64x | 4/28 |
| D/E Ratio | 0.40x | 26/53 |
| Financial Leverage | 1.40x | 26/52 |
| Interest Coverage | 2.3x | 12/37 |
| Working Capital | $1.07B | 12/59 |
| Metric | RGEN | Rank |
|---|---|---|
| Operating Cash Flow | $135M | 14/57 |
| Free Cash Flow | $112M | 13/50 |
| Capital Spending | -$23M | 38/50 |
| OCF Growth YoY | 2.1% | 11/16 |
| FCF Growth YoY | 2.8% | 8/15 |
| FCF/Sales | 14.3% | 13/32 |
| CapEx/Sales | 2.9% | 20/32 |
| Metric | RGEN | Rank |
|---|---|---|
| Asset Turnover | 0.27x | 22/36 |
| Receivables Turnover | 5.0x | 14/24 |
| Inventory Turnover | 1.9x | 17/23 |
| Fixed Assets Turnover | 4.7x | 16/37 |
| Days Sales Outstanding | 73 days | 11/24 |
| Days Inventory | 188 days | 7/23 |
| Payables Period | 33 days | 21/26 |
| Cash Conversion Cycle | 228 days | 3/18 |
| Metric | RGEN | Rank |
|---|---|---|
| Total Revenue | $785M | 12/37 |
| Operating Income | $65M | 13/54 |
| Net Income | $42M | 13/50 |
| R&D Expense | $56M | 52/56 |
| SG&A Expense | $301M | 11/22 |
| Cost of Goods Sold | $362M | 10/26 |
| Metric | RGEN | Rank |
|---|---|---|
| Shares Outstanding | 56M | – |
| Total Current Assets | $1.20B | 40.7% of assets |
| Cash & Short-term Investments | $607M | 20.6% of assets |
| Accounts Receivable | $158M | 5.3% of assets |
| Inventory | $187M | 6.3% of assets |
| Total Liabilities | $838M | 28.4% of assets |
| Short-term Debt | $99M | 3.4% of assets |
Companies classified under the same SEC industry code as Repligen Corp (Biological Products, (No Diagnostic Substances)): 60 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| RGEN Repligen Corp | ▲ | $9.90B |
| AMGN Amgen Inc | ▼ | $233.82B |
| GILD Gilead Sciences, Inc. | ▲ | $193.67B |
| MRNA Moderna, Inc. | ▲ | $87.04B |
| ARGX Argenx Se | ▼ | $50.69B |
| RVMD Revolution Medicines, Inc. | ▲ | $38.14B |
| BIIB Biogen Inc. | ▼ | $34.13B |
| BNTX Biontech Se | ▲ | $22.18B |
| EXEL Exelixis, Inc. | ▶ | $15.42B |
| HALO Halozyme Therapeutics, Inc. | ▶ | $13.83B |
| NBIX Neurocrine Biosciences Inc | ▲ | $13.79B |
| TECH Bio-Techne Corp | ▼ | $11.38B |
| QGEN Qiagen N.V. | ▶ | $10.01B |
| IBRX Immunitybio, Inc. | ▲ | $9.73B |
| PCVX Vaxcyte, Inc. | ▲ | $9.47B |
| KRYS Krystal Biotech, Inc. | ▶ | $9.37B |
| KYMR Kymera Therapeutics, Inc. | ▲ | $8.71B |
| TWST Twist Bioscience Corp | ▲ | $8.32B |
| IOVA Iovance Biotherapeutics, Inc. | ▲ | $6.17B |
| IMVT Immunovant, Inc. | ▲ | $5.52B |
| KOD Kodiak Sciences Inc. | ▲ | $5.39B |
| CGON Cg Oncology, Inc. | ▲ | $5.31B |
| SRRK Scholar Rock Holding Corp | ▲ | $4.86B |
| CRSP Crispr Therapeutics Ag | ▲ | $4.76B |
| ADPT Adaptive Biotechnologies Corp | ▲ | $3.83B |
| RLAY Relay Therapeutics, Inc. | ▲ | $3.57B |
| TARS Tarsus Pharmaceuticals, Inc. | ▲ | $2.99B |
| DNLI Denali Therapeutics Inc. | ▼ | $2.81B |
| BEAM Beam Therapeutics Inc. | ▲ | $2.42B |
| ADMA Adma Biologics, Inc. | ▼ | $2.39B |
| LIFE Atyr Pharma Inc | ▲ | $2.37B |
| RXRX Recursion Pharmaceuticals, Inc. | ▲ | $2.07B |
| VCEL Vericel Corp | ▶ | $2.05B |
| BCRX Biocryst Pharmaceuticals Inc | ▲ | $1.99B |
| NVAX Novavax Inc | ▲ | $1.86B |
| ALVO Alvotech | ▲ | $1.78B |
| MESO Mesoblast Ltd | ▶ | $1.70B |
| VIR Vir Biotechnology, Inc. | ▲ | $1.69B |
| MAZE Maze Therapeutics, Inc. | ▲ | $1.53B |
| IMCR Immunocore Holdings Plc | ▶ | $1.51B |
| COAG Hemab Therapeutics Holdings, Inc. | ▶ | $1.40B |
| TSHA Taysha Gene Therapies, Inc. | ▲ | $1.18B |
| VOR Vor Biopharma Inc. | ▲ | $1.07B |
| REPL Replimune Group, Inc. | ▲ | $1.02B |
| JATT Zura Bio Ltd | ▶ | $994M |
| IMTX Immatics N.V. | ▲ | $902M |
| MGTX Meiragtx Holdings Plc | ▶ | $891M |
| SLBT Sl Science Holding Ltd | ▶ | $884M |
| CGEM Cullinan Therapeutics, Inc. | ▲ | $832M |
| GLUE Monte Rosa Therapeutics, Inc. | ▲ | $831M |
| ODTX Odyssey Therapeutics, Inc. | ▲ | $825M |
| DNA Ginkgo Bioworks Holdings, Inc. | ▲ | $692M |
| SANA Sana Biotechnology, Inc. | ▲ | $680M |
| FDMT 4d Molecular Therapeutics, Inc. | ▲ | $670M |
| AURA Aura Biosciences, Inc. | ▲ | $633M |
| PRME Prime Medicine, Inc. | ▲ | $629M |
| CADL Candel Therapeutics, Inc. | ▲ | $627M |
| SLDB Solid Biosciences Inc. | ▲ | $593M |
| DBVT Dbv Technologies S.A. | ▶ | $536M |
| VALN Valneva Se | ▼ | $505M |
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
On September 3, 2026, REPLIGEN CEO Loeillot Olivier forfeited 2,842 shares at $169.61 each, followed by a sale of 3,035 shares at $165.90 per share on September 4, 2026. As a result, his reported ...
Our AI ranks Repligen Corp outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
For RGEN, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 62.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 54.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Repligen Corp forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 16, 2026.
60 issuers in our coverage, RGEN included, share the SEC industry code Biological Products, (No Diagnostic Substances). The largest are: Amgen Inc (AMGN), Gilead Sciences, Inc. (GILD), Moderna, Inc. (MRNA), Argenx Se (ARGX), Revolution Medicines, Inc. (RVMD), Biogen Inc. (BIIB).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.
Signals, companies, plans: answered from live data.
I read Intratio's daily model signals, company data and your account to answer in seconds, in your language.